Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10 Retraction in /10.3892/mmr.2023.13109

Zhou,Zhen; Zhao,Yi; Gu,Lingping; Niu,Xiaoming; Lu,Shun

doi:10.3892/mmr.2017.8173

Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10

Retraction in: /10.3892/mmr.2023.13109

Authors:
- Zhen Zhou
- Yi Zhao
- Lingping Gu
- Xiaoming Niu
- Shun Lu
View Affiliations

Affiliations: Department of Lung Tumor Clinical Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, P.R. China
Published online on: November 28, 2017 https://doi.org/10.3892/mmr.2017.8173
Pages: 2153-2160
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of global cancer‑associated mortality. Genomic alterations in lung cancers have not been widely characterized, however, the molecular mechanism of tumor initiation and progression remain unknown, and no molecularly targeted have been specifically developed for its treatment and diagnosis. The present study observed the upregulation of Aldo‑keto reductase family 1 member Bio10 (AKR1B10) lung cancer tissues by analyzing two public lung cancer gene expression datasets. Further experiments in silencing AKR1B10 demonstrated that the expression of AKR1B10 was associated with cell proliferation, cell cycle, adhesion and invasion, as well as extracellular‑signal‑regulated kinase/mitogen activated protein kinase signal pathway. The overexpression of AKR1B10 in lung cancer indicates the important role of AKR1B10 in tumorigenesis. These findings suggest that AKR1B10 could be a potential diagnosis and treatment mark of lung cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hensing T, Chawla A, Batra R and Salgia R: A personalized treatment for lung cancer: Molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 799:85–117. 2014. View Article : Google Scholar : PubMed/NCBI
3	Nanavaty P, Alvarez MS and Alberts WM: Lung cancer screening: Advantages, controversies, and applications. Cancer Control. 21:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
4	Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, et al: Progression-free and overall survival in Alk-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res. 21:2745–2752. 2015. View Article : Google Scholar : PubMed/NCBI
5	Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C and Song Y: SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol. 35:6073–6082. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY and Chen YB: JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor. Oncotarget. 6:14329–14343. 2015. View Article : Google Scholar : PubMed/NCBI
7	Nishinaka T, Miura T, Sakou M, Hidaka C, Sasaoka C, Okamura A, Okamoto A and Terada T: Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway. Chem Biol Interact. 234:274–281. 2015. View Article : Google Scholar : PubMed/NCBI
8	Cao D, Fan ST and Chung SS: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem. 273:11429–11435. 1998. View Article : Google Scholar : PubMed/NCBI
9	Penning TM: AKR1B10: A new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res. 11:1687–1690. 2005. View Article : Google Scholar : PubMed/NCBI
10	Fukumoto S, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H, Yamamoto S, et al: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res. 11:1776–1785. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kang MW, Lee ES, Yoon SY, Jo J, Lee J, Kim HK, Choi YS, Kim K, Shim YM, Kim J and Kim H: AKR1B10 is associated with smoking and smoking-related non-small-cell lung cancer. J Int Med Res. 39:78–85. 2011. View Article : Google Scholar : PubMed/NCBI
12	Chung YT, Matkowskyj KA, Li H, Bai H, Zhang W, Tsao MS, Liao J and Yang GY: Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma. Mod Pathol. 25:758–766. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tarca AL, Lauria M, Unger M, Bilal E, Boue S, Kumar Dey K, Hoeng J, Koeppl H, Martin F, Meyer P, et al: Strengths and limitations of microarray-based phenotype prediction: Lessons learned from the IMPROVER diagnostic signature challenge. Bioinformatics. 29:2892–2899. 2013. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Huang C, Verhulst S, Shen Y, Bu Y, Cao Y, He Y, Wang Y, Huang D, Cai C, Rao K, et al: AKR1B10 promotes breast cancer metastasis through integrin α5/δ-catenin mediated FAK/Src/Rac1 signaling pathway. Oncotarget. 7:43779–43791. 2016. View Article : Google Scholar : PubMed/NCBI
16	Zemanova L, Hofman J, Novotna E, Musilek K, Lundova T, Havrankova J, Hostalkova A, Chlebek J, Cahlikova L and Wsol V: Flavones inhibit the activity of AKR1B10, a promising therapeutic target for cancer treatment. J Nat Prod. 78:2666–2674. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cao Z, Zhou B, Chen X, Huang D, Zhang X, Wang Z, Huang H, Wang Y and Cao D: Statil suppresses cancer cell growth and proliferation by the inhibition of tumor marker AKR1B10. Anticancer Drugs. 25:930–937. 2014. View Article : Google Scholar : PubMed/NCBI
18	Balendiran GK, Martin HJ, El-Hawari Y and Maser E: Cancer biomarker AKR1B10 and carbonyl metabolism. Chem Biol Interact. 178:134–137. 2009. View Article : Google Scholar : PubMed/NCBI
19	Huang L, He R, Luo W, Zhu YS, Li J, Tan T, Zhang X, Hu Z and Luo D: Aldo-Keto reductase family 1 member B10 inhibitors: Potential drugs for cancer treatment. Recent Pat Anticancer Drug Discov. 11:184–196. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhong L, Liu Z, Yan R, Johnson S, Zhao Y, Fang X and Cao D: Aldo-keto reductase family 1 B10 protein detoxifies dietary and lipid-derived alpha, beta-unsaturated carbonyls at physiological levels. Biochem Biophys Res Commun. 387:245–250. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF and Cao D: Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 283:3418–3423. 2008. View Article : Google Scholar : PubMed/NCBI
22	Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993. View Article : Google Scholar : PubMed/NCBI
23	Zhang XQ, Yang CY, Rao XF and Xiong JP: Plumbagin shows anti-cancer activity in human breast cancer cells by the upregulation of p53 and p21 and suppression of G1 cell cycle regulators. Eur J Gynaecol Oncol. 37:30–35. 2016.PubMed/NCBI
24	Alldridge LC and Bryant CE: Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp Cell Res. 290:93–107. 2003. View Article : Google Scholar : PubMed/NCBI
25	Osaki LH and Gama P: MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci. 14:10143–10161. 2013. View Article : Google Scholar : PubMed/NCBI
26	Li J, Guo Y, Duan L, Hu X, Zhang X, Hu J, Huang L, He R, Hu Z, Luo W, et al: AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 8:33694–33703. 2017.PubMed/NCBI